

APPENDIX 4

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy						
	Overall Cohort	Additionally Treated[a]			Supportive Care Only[a]	
	Periods Of All-Cause Utilization and Costs Assessment [b]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)
All-cause Inpatient Services						
<i>Had ≥1 hospital admission, n (%)</i>	2410 (93)	1163 (82)	924 (65)	733 (52)	846 (72)	883 (76)
<i>Number of unique admissions</i>						
Mean	3	2	1	1	1	2
SD	2	2	1	2	2	2
Median	3	2	1	1	1	1
<i>Total days in hospital</i>						
Mean	23	15	9	7	10	12
SD	23	19	13	14	16	15
Median	16	9	5	1	5	8
<i>Total inpatient costs (2012 US \$)</i>						
Mean	\$51,672	\$29,271	\$23,223	\$14,320	\$20,525	\$30,152
SD	\$50,662	\$35,907	\$30,586	\$25,719	\$34,129	\$38,148
Median	\$38,792	\$18,701	\$12,523	\$4850	\$11,054	\$19,435
All-cause ED Visits						
<i>Had ≥1 ED visit, n (%)</i>	2160 (84)	1079 (76)	677 (48)	694 (49)	760 (65)	656 (56)

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy

	Overall Cohort	Additionally Treated[a]				Supportive Care Only[a]
	Periods Of All-Cause Utilization and Costs Assessment [b]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)
<i>Number of ED visits</i>)	
Mean	3	3	2	2	2	2
SD	3	3	1	2	2	2
Median	3	2	1	2	1	1
<i>Total ED costs (2012 US \$)</i>						
Mean	\$416	\$320	\$128	\$159	\$205	\$171
SD	\$468	\$392	\$214	\$279	\$336	\$263
Median	\$303	\$207	\$0	\$0	\$146	\$98
All-cause Office or Specialist Visits						
<i>Had ≥1 office or specialist visit, n (%)</i>	2581 (100)	1411 (100)	1415 (100)	1408 (100)	1087 (93)	1166 (100)
<i>Number of office visits</i>						
Mean	66	49	30	29	20	30
SD	58	47	25	33	43	30
Median	48	34	23	18	7	21
<i>Total office or specialist visit costs (2012 US\$)</i>						
Mean	\$27,843	\$21,346	\$15,431	\$11,727	\$3813	\$13,207

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy

	Overall Cohort	Additionally Treated[a]				Supportive Care Only[a]	
	Periods Of All-Cause Utilization and Costs Assessment [b]						
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)	
SD	\$32,413	\$30,370	\$15,474	\$14,405	\$8,209	\$16,121	
Median	\$17,104	\$10,969	\$10,403	\$6,416	\$1,304	\$8,088	
All-cause Hospital Outpatient Visits							
<i>Had ≥1 hospital outpatient visit, n (%)</i>	2545 (99)	1334 (94)	1367 (97)	1231 (87)	765 (65)	1115 (95)	
<i>Number of hospital outpatient visits</i>							
Mean	20	15	10	9	5	9	
SD	23	21	10	16	12	10	
Median	13	9	7	5	1	6	
<i>Total hospital outpatient costs (2012 US \$)</i>							
Mean	\$11,825	\$8868	\$6797	\$5657	\$1762	\$5411	
SD	\$20,485	\$19,855	\$9223	\$16,748	\$10,797	\$8347	
Median	\$6182	\$3459	\$4070	\$1800	\$280	\$2755	
All-cause Hospice Visits							
<i>Had ≥1 hospice service, n (%)</i>	1399 (54)	790 (56)	4 (0)	215 (15)	608 (52)	7 (1)	

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy

	Overall Cohort	Additionally Treated[a]				Supportive Care Only[a]	
	Periods Of All-Cause Utilization and Costs Assessment [b]						
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)	
<i>Number of hospice visits</i>							
Mean	1	1	0	0	1	0	
SD	2	2	0	1	2	0	
Median	1	1	0	0	1	0	
<i>Total hospice costs (2012 US \$)</i>							
Mean	\$3578	\$3668	\$32	\$1311	\$3380	\$50	
SD	\$7901	\$8082	\$766	\$5551	\$7355	\$918	
Median	\$547	\$677	\$0	\$0	\$381	\$0	
All-cause SNF Care							
<i>Had ≥1 SNF admission, n (%)</i>	598 (23)	252 (18)	101 (7)	131 (9)	182 (16)	133 (11)	
<i>Number of SNF admissions</i>							
Mean	0	0	0	0	0	0	
SD	1	1	0	1	1	0	
Median	0	0	0	0	0	0	
<i>Total SNF care costs (2012 US \$)</i>							
Mean	\$2989	\$2282	\$712	\$1183	\$1742	\$1240	
SD	\$7836	\$6763	\$3542	\$4919	\$6400	\$4633	
Median	\$0	\$0	\$0	\$0	\$0	\$0	
All-cause Outpatient							

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy

	Overall Cohort	Additionally Treated[a]			Supportive Care Only[a]	
	Periods Of All-Cause Utilization and Costs Assessment [b]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)
Pharmacy						
<i>Had ≥1 outpatient pharmacy encounter, n (%)</i>	472 (18)	271 (19)	152 (11)	218 (15)	178 (15)	139 (12)
<i>Number of outpatient pharmacy encounters</i>						
Mean	10	10	2	5	5	3
SD	35	33	10	24	24	16
Median	0	0	0	0	0	0
<i>Total outpatient pharmacy encounter costs (2012 US \$)</i>						
Mean	\$844	\$764	\$283	\$386	\$331	\$266
SD	\$5070	\$4155	\$3486	\$2696	\$1980	\$2059
Median	\$0	\$0	\$0	\$0	\$0	\$0
All-cause Ancillary Care						
<i>Had ≥1 ancillary care visit, n (%)</i>	2112 (82)	1064 (75)	908 (64)	834 (59)	588 (50)	766 (66)
<i>Number of ancillary care visits</i>						
Mean	8	6	3	3	3	3
SD	12	10	5	6	8	6
Median	4	3	1	1	1	1
<i>Total ancillary care costs (2012</i>						

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy

	Overall Cohort	Additionally Treated[a]				Supportive Care Only[a]	
	Periods Of All-Cause Utilization and Costs Assessment [b]						
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)	
<i>US \$)</i>							
Mean	\$5620	\$4075	\$2277	\$2326	\$1874	\$2858	
SD	\$9634	\$8221	\$4351	\$5604	\$6714	\$4947	
Median	\$2824	\$1160	\$476	\$197	\$0	\$713	
All-cause Total Health Care Utilization							
<i>Had ≥1 medical encounter, n (%)</i>	2583 (100)	1415 (100)	1415 (100)	1415 (100)	1149 (98)	1168 (100)	
<i>Number of encounters</i>							
Mean	111	86	48	49	36	49	
SD	99	85	39	64	72	48	
Median	81	59	37	30	13	36	
<i>Total costs (2012 US \$)</i>							
Mean	\$104,786	\$70,594	\$48,884	\$37,068	\$33,633	\$53,355	
SD	\$76,671	\$61,762	\$41,489	\$41,681	\$46,869	\$49,665	
Median	\$86,288	\$53,680	\$38,300	\$23,890	\$18,914	\$41,729	

ED = emergency department; SD = standard deviation; SNF = skilled nursing facility; US = United States

[a] Patients receiving cancer-related treatments after the first-line chemotherapy completion date were categorized as “additionally treated,” and the remaining patients were classified as “supportive care only.”

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment Cohort and Line of Therapy

	Overall Cohort	Additionally Treated[a]			Supportive Care Only[a]	
	Periods Of All-Cause Utilization and Costs Assessment [b]					
	Overall Follow-up (N = 2583) n (%)	All Post-first-line Chemotherapy (N = 1415) n (%)	First-line Chemotherapy (N = 1415) n (%)	Second-line Chemotherapy (N = 1415) n (%)	All Post-first-line Chemotherapy (N = 1168) n (%)	First-line Chemotherapy (N = 1168) n (%)
<p>[b] Gastric cancer-related health care utilization and costs were assessed during the following pre-defined periods of assessment: (1) Overall follow-up period: the period between the index gastric cancer diagnosis date and death or the end of the database (December 31, 2009), whichever occurred first; (2) Post-first-line chemotherapy period: the period between the day immediately following the first-line chemotherapy administration end date and death or the end of the database, whichever occurred first; (3) First-line chemotherapy period: the period between the gastric cancer index date and the first-line chemotherapy regimen end date; and (4) Second-line chemotherapy period: the period between the day immediately following the first-line chemotherapy regimen end date and the last date of the second-line chemotherapy regimen among patients who initiated second-line chemotherapy.</p>						